Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kissei Pharmaceutical Co. Ltd.

Latest From Kissei Pharmaceutical Co. Ltd.

Glenmark’s Remogliflozin Hopes To Shake Up Indian SGLT2i Market

Glenmark’s remogliflozin is priced about 50% lower than the other SGLT2 inhibitors in India and is expected to expand access to the class of drugs significantly. Early physician outlook for the new SGLT2 inhibitor appears encouraging.

India Pricing Strategies

Purple Patch For Pharma/Biotech R&D As NAS Launches Reach Record High

The pharma and biotech industries enjoyed their most productive year since the turn of the century in terms of number of novel products launched worldwide in 2018.

Launches Analysis

Korea IND Filing Moves Alteogen's Eylea Biosimilar Forward

South Korean biotech Alteogen is progressing the development of its Eylea biosimilar both at home and abroad, with the hope of becoming a global first mover with its version in wet AMD, backed by formulation and manufacturing patents.

South Korea Biosimilars

Deal Watch: Purdue Continues Move Away From Opioids With Alivio Deal

In its continuing efforts to diversify away from opioid pain drugs, Purdue partners on non-opioid program with Alivio. Rigel licenses Tavalisse rights in all indications go to Spain’s Grifols.

Deals Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Kissei Pharmaceutical Co. Ltd.
  • Senior Management
  • Mutsuo Kanzawa, Chmn. & CEO
    Yoshio Furihata, Pres. & COO
  • Contact Info
  • Kissei Pharmaceutical Co. Ltd.
    Phone: (81) 263 25 9081
    19-48, Yoshino
    Matsumoto City, 399 8710